CA15-3

Aliases:
This biomarker is also known as:
  • Carcinoma-Associated Mucin
  • PEM
  • PEMT
  • EMA
  • Medullary Cystic Kidney Disease 1 (Autosomal Dominant)
  • ADMCKD
  • Mucin 1, Transmembrane
  • Mucin 1, Cell Surface Associated
  • MCKD1
  • MUC-1
  • MUC1/ZD
  • Krebs Von Den Lungen-6
  • Tumor Associated Epithelial Mucin
  • DF3 Antigen
  • MUC-1/SEC
  • KL-6
  • CA15.3
  • PUM
  • H23 Antigen
  • CA15-3
  • Mucin-1
  • Peanut-Reactive Urinary Mucin
  • Cancer Antigen 15-3
  • MAM6
  • CA 15-3
  • Breast Carcinoma-Associated Antigen DF3
  • MCD
  • Polymorphic Epithelial Mucin
  • MCKD
  • Tumor-Associated Epithelial Membrane Antigen
  • MUC1
  • Medullary Cystic Kidney Disease, Autosomal Dominant
  • CD227 Antigen
  • CD227
  • ADMCKD1
  • Episialin
  • MUC-1/X
  • H23AG
  • Tumor-Associated Mucin

Description…

From NCBI Gene: This gene encodes a membrane-bound protein that is a member of the mucin family. Mucins are O-glycosylated proteins that play an essential role in forming protective mucous barriers on epithelial surfaces. These proteins also play a role in intracellular signaling. This protein is expressed on the apical surface of epithelial cells that line the mucosal surfaces of many different tissues including lung, breast stomach and pancreas. This protein is proteolytically cleaved into alpha and beta subunits that form a heterodimeric complex. The N-terminal alpha subunit functions in cell-adhesion and the C-terminal beta subunit is involved in cell signaling. Overexpression, aberrant intracellular localization, and changes in glycosylation of this protein have been associated with carcinomas. This gene is known to contain a highly polymorphic variable number tandem repeats (VNTR) domain. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Feb 2011]

Attributes
QA State: Accepted
Type: Protein
HGNC Name: MUC1

The following organs have data associated with this biomarker…

Attributes

Phase: 3
QA State: Curated
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access to this biomarker.

Attributes

Phase: 2
QA State: Under Review
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access to this biomarker.

Attributes

Phase: 3
QA State: Accepted

Overview

CA15-3 may be a molecular marker for ovarian cancer. Literature suggests that the concomitant measurement of CA15-3 with CA125 could be advantageous in the pre-operative discrimination of benign and malignant ovarian tumors.

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. CA15-3 alone was not a strong predictor.

Supporting Study Data

The following studies/protocols provide evidence supporting CA15-3 indications for the Ovary…

PLCO Ovarian Phase III Validation Study

Our preliminary data indicate that the performance of CA 125 as a screening test for ovarian cancer can be improved upon by additional biomarkers. With completion of one additional validation step, we will be ready to test the performance of a consensus marker panel in a phase III validation study. Given the original aims of the PLCO trial, we believe that the PLCO represents an ideal longitudinal cohort offering specimens for phase III validation of ovarian cancer biomarkers.

View more about this study
Biomarker Characteristics Summary

No statistics found.

Decision Rule

PMID:21372037

Additional Study-Specific Protocols
Study-Specific Publications

No study-specific publications defined.

Study-Specific Resources

No study-specific resources defined.

SPORE/EDRN/PRE-PLCO Ovarian Phase II Validation Study

Create a new set of phase II specimens (160 cases with pre-operative bloods representing major histologic types and including 80 early-staged and 80 late-staged cases, 160 controls with benign disease, 480 general population controls, and a small set of serial Samples collected either at least 3 months apart, but not more than 6 months apart OR between 10 months apart and no more than 14 months apart in 40 healthy controls) will be used to evaluate markers identified in preliminary work. The top 5-10 markers, plus an expanded panel of Luminex markers, will comprise a “working consensus panel” for subsequent analysis in PLCO specimens.

View more about this study
Biomarker Characteristics Summary

No statistics found.

Decision Rule

PMID:21372037

Additional Study-Specific Protocols
Study-Specific Publications

No study-specific publications defined.

Study-Specific Resources

No study-specific resources defined.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

Organ-Specific Resources

No organ-specific resources defined.

Attributes

Phase: 1
QA State: Under Review
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access to this biomarker.
Version 5.1.0